article thumbnail

Enhancing Cardiovascular Health in End-Stage Kidney Disease, with Maya N. Clark-Cutaia, PhD, RN

HCPLive

Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.

RN 59
article thumbnail

Advance in the Treatment of Acute Heart Failure Identified

DAIC

The drug, dapagliflozin, was initially approved for the treatment of Type 2 diabetes, but it since has been shown to reduce the risk of hospitalization for heart failure and death in patients with serious health problems that include heart and chronic kidney disease and heightened cardiovascular risk.